Bayer Aktiengesellschaft

Bayer Pharma Aktiengesellschaft

The Broad Institute, Inc.

Till Freudenberger

Alexander Straub

Alexandros Vakalopoulos

Hanna Tinel

Tobias Marquardt

Henrik Teller

Matthias Beat Wittwer

Thomas Mondritzki

Melissa Boultadakis Arapinis

Markus Brechmann

Pierre Wasnaire

Daniel Meibom

Yolanda Cancho Grande

Dmitry Zubov

Sarah Anna Liesa Johannes

Damian Brockschnieder

Maximillian Andreas Kullmann

Kristin Beyer

Dzianis Menshykau

Bryan Macdonald

Yi Xing

Tanja Krainz

Nadine Elowe

Guzman Sanchez

Maximilian Andreas Kullmann

The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. Ris hydrogen, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or phenyl; Ris hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R, R, R, R, Rand Rare independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R, R, Ris H; X, X, X, X, Xand Xare independently N or C; with the proviso that in each ring maximal one X is N.

Substituted hydantoinamides as ADAMTS7 antagonists

The present application relates to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.

7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof

Growing community of inventors

Velbert, Germany

Till Freudenberger